Multidrug-Resistant Tuberculosis and Implementation of Control Measures in Ketapang District, West Borneo, Indonesia

Imelda Nita Saputri, Eva Lydia Munthe


Background: Multidrug-resistant Tuberculosis (MDR-TB) has emerged as a threat of public health in Indonesia. The utilization of GeneXpert MTB/RIF as a rapid yet effective diagnostic tool enables early and appropriate treatment initiation of MDR-TB. This study aims in describing the occurrence of MDR-TB and the implementation of control measures in Ketapang District, West Borneo, Indonesia, since the utilization of GeneXpert MTB/RIF as a diagnostic tool.
Methods: This is a cross-sectional descriptive study. The data were taken from medical record of patients with MDR-TB in Dr.Agoesdjam District General Hospital. The diagnosis was obtained from PCR-based analysis GeneXpert MTB/RIF of sputum sample, which detected Mycobacterium tuberculosis resistant to Rifampicin.
Results: Seventeen subjects were included in the study. Subjects were 8 (47%) male and 9 (53%) female aged 24-75 years. Most subjects are farmers (35.3%) or housewives (35.3%), and did not receive formal education (41.2%). The main symptom reported upon admission was cough (41.2%). Direct microscopic smear of sputum detected acid-fast bacilli of +2 (29.4%) and +1 (29.4%) the most. The most common feature seen in thoracic X-ray was infiltrate in 100% of cases. Four subjects (23.5%) have type II diabetes mellitus, while one subject (5.9%) is infected with HIV. Subjects are categorized into new case (17.6%), failure of category 1 treatment (41.2%), and failure of category 2 treatment (41.2%). Treatment for MDR-TB has been initiated since 2014, while two subjects have not started taking the regimen. Among 15 subjects receiving treatment, one (6.7%) was recovered, 6 (40%) subjects deceased, and 8 (53.3%) subjects are currently still taking the regimen, while conversion occurred in 8 (53.3%) subjects.
Conclusion: Using the GeneXpert MTB/RIF analysis, 17 cases of MDR-TB have been detected in Ketapang district. Management of MDR-TB has been conducted since 2014.


MDR-TB, Multidrug-resistant Tuberculosis, Ketapang

Full Text:



Kementerian Kesehatan RI, Direktorat Jenderal Pengendalian Penyakit dan Penyehatan Lingkungan. Pedoman Nasional Pengendalian Tuberkulosis. Jakarta: Kementerian Kesehatan RI; 2014.

Lisdawati V, Puspandari N, Rif’ati L, Soekarno T, Melatiwati M, Syamsidar K, et al. Molecular epidemiology study of Mycobacterium tuberculosis and its susceptibility to anti-tuberculosis drugs in Indonesia. BMC Infect Dis. 2015;15(366).

WHO. Global Tuberculosis Report 2014. Geneva: World Health Organization; 2014.

Centers for Disease Control and Prevention. Availability of An Assay for Detecting Mycobacterium tuberculosis, Including Rifampin-Resistant Strains, and Considerations of Its Use. MMWR. 2013;62(41):821-4.

WHO. Automated Real-Time Nucleic Acid Amplification Technology for Rapid and Simultenous Detection of Tuberculosis and Rifampicin Resistance: Xpert MTB/RIF System. Policy Statement. Geneva: World Health Organization; 2011.

van Kampen S, Susanto NH, Simon S, Astiti SD, Chandra R, Burhan E, et al. Effects of introducing Xpert MTB/RIF on diagnosis and treatment of drug-resistant tuberculosis patients in Indonesia: A pre-post intervention study. PLos One. 2015;10(6).

Kementerian Kesehatan RI, Badan Peneltian dan Pengembangan Kesehatan. Riset Kesehatan Dasar 2013. Jakarta: Kementerian Kesehatan RI; 2013.

Pradipta I, Forsman LD, Bruchfeld J, Hak E, Alffenaar JW. Risk factors of multidrug-resistant tuberculosis: A global systematic review and meta-analysis. Journal of Infection. 2018.

Wu B, Zhang L, Liu Z, He H, Pan A, Wang F, et al. Drug-resistant tuberculosis in Zhejiang Province, China: an updated analysis of time trends, 1999–2013. Glob Health Action. 2017;10(1).

Chan C, Bognar FA, Wong KH, Leung CC, Tam CM, Chan KCW, et al. The epidemiology and clinical manifestations of Human Immunodeficiency virus-associated tuberculosis in Hong Kong. Hong Kong Med J. 2010;16(3):192-8.

Verdecchia M, Keus K, Blankley S, Vambe D, Ssonko C, Piening T, et al. Model of care and risk factors for poor outcomes in patients on multi-drug resistant tuberculosis treatment at two facilities in eSwatini (formerly Swaziland), 2011–2013. PLoS One. 2018;13(10).

Zhang L, Pang Y, Yu X, Wang Y, Lu J, Gao M, et al. Risk factors for pulmonary cavitation in tuberculosis patients from China. Emerg Microbes Infect. 2016;5(10):e110.

Chuang P, Wu MH, Fan SY, Lin KY, Jou R. Population-based drug resistance surveillance of multidrug-resistant tuberculosis in Taiwan, 2007-2014. PLos One. 2016;11(11).

He X, Tao NN, Liu Y, Zhang XX, Li HC. Epidemiological trends and outcomes of extensively drug-resistant tuberculosis in Shandong, China. BMC Infect Dis. 2017;17:555.

Jaeger S, Juarez-Espinosa OH, Candemir S, Poostchi M, Yang F, Kim L, et al. Detecting drug-resistant tuberculosis in chest radiographs. International Journal of Computer Assisted Radiology and Surgery. 2018;13:1915-25.

Ronacher K, Joosten SA, van Crevel R, Dockrell HM, Walzl G, Ottenhoff THM. Acquired immunodeficiencies and tuberculosis: Focus on HIV/AIDS and diabetes mellitus. Immunol Rev. 2015;264:121-37.

Dooley K, Chaisson RE. Tuberculosis and diabetes mellitus: Convergence of two epidemics. Lancet Infect Dis. 2009;9(12):737-46.

Kidenya B, Webster LE, Behan S, Kabangila R, Peck RN, Mshana SE, et al. Epidemiology and genetic diversity of multidrug-resistant tuberculosis in East Africa. Tuberculosis (Edinb). 2014;94(1).

Monge S, Diez M, Pulido F, Iribarren JA, Campins AA, Arazo P, et al. Tuberculosis in a cohort of HIV-positive patients: epidemiology, clinical practice and treatment outcomes. Int J Tuberc Lung Dis. 2014;18(6):700-8.

Kapur A, Harries AD. The double burden of diabetes and tuberculosis - Public health implication. Diabetes Res Clin Pract. 2013;101:10-9.

Bailey S, Grant P. ‘The Tubercular Diabetic’: The impact of diabetes mellitus on tuberculosis and its threat to global tuberculosis control. Clinical Medicine. 2011;11(4):344-7.

Development NIoHRa. National Report: Basic Health Research. Jakarta: Development NIoHRa; 2011.

Dheda KGT, Gandhi NR, Murray M, Theron G, Udwadia Z, et al. Global control of tuberculosis: from extensively drug-resistant to untreatable tuberculosis. Lancet Respir Med. 2014;2(4):321-38.

Rumende CM. Risk factors for multidrug-resistant tuberculosis. Acta Med Indones. 2018;50(1):1-2.

Ragonnet R, Trauer JM, Denholm JT, Marais BJ, McBryde ES. High rates of multidrug-resistant and rifampicin-resistant tuberculosis among re-treatment cases: Where do they come from? BMC Infect Dis. 2017;17(1):36.

Alisjahbana B, Sahiratmadja E, Nelwan EJ, et al. The effect of type 2 diabetes mellitus on the presentation and treatment response of pulmonary tuberculosis. Clin Infect Dis. 2007;45:428-35.

Lv L, Li T, Xu K, Shi P, He B, Kong W, et al. Sputum bacteriology conversion and treatment outcome of patients with multidrug-resistant tuberculosis. Infect Drug Resist. 2018;11:147-54.

Alene K, Yi HZ, Viney K, McBryde ES, Yang KY, Bai LQ, et al. Treatment outcomes of patients with multidrug-resistant and extensively drug resistant tuberculosis in Hunan Province, China. BMC Infect Dis. 2017;17:573.

van Altena R, de Vries G, Haar CH, de Lange WCM, Magis-Escurra C, van den Hof S, et al. Highly successful treatment outcome of multidrug-resistanttuberculosis in the Netherlands, 2000–2009. Int J Tuberc Lung Dis. 2015;19(4):406-12.



  • There are currently no refbacks.

Jurnal Respirologi Indonesia
pISSN: 0853-7704 - eISSN: 2620-3162
Address: Jalan Cipinang Bunder No. 19, Cipinang, Pulogadung, Jakarta Timur, DKI Jakarta 13240, Indonesia
Phone: +62-21-2247-4845

An official publication by
the Indonesian Society of Respirology (ISR)

Creative Commons License
Creative Commons Attribution-NonCommercial 4.0 International License